High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer

Journal of Chemotherapy

Volumn 12, Issue 5, 2000, Pages 446-453

  Bosnjak, S M ^a   Neskovic Konstantinovic, Z B ^a   Radulovic, S S ^a   Susnjar, S ^a   Mitrovic, L B ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Acute emesis; Breast cancer; Doxorubicin based chemotherapy; Ondansetron; Single dose schedule

Indexed keywords

ALPRAZOLAM; ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; KLOMETOL; METOCLOPRAMIDE; ONDANSETRON;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NERVOUSNESS; RANDOMIZATION; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0033756591     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2000.12.5.446     Document Type: Article

References (32)

1. A prospective randomised phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin
2. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens
3. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
4. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies
5. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy
6. Tolerancia, toxicidad y aceptation del tratamiento quimioterapico adyuvante FAC (5-fluorouracilo, adriamicina y ciclofosfamida) en el cancer de mama. Analisis de 100 enfermas consecutivas
7. A randomized double blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy
8. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study
9. Upadhyaya. Double blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide
10. Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomized, parallel group study
11. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallelgroup study
12. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
13. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic therapy - A randomised study
14. Oral treatment with ondansetron in the outpatient setting
15. Oral ondansetron administered either as a single daily or twice daily dose in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
16. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group
17. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting
18. 3 antagonist in the prevention of acute emesis related to highly emetogenic chemotherapy (dose, schedule, and route of administration)
19. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicentre, double-blind, double-dummy, randomised, parallel group study
20. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy - Induced acute nausea and vomiting
21. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer
22. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: A double blind, placebo-controlled study assessing the usefulness of alprazolam
23. Methodology of trials with antiemetics
24. Proposal for classifying the acute emetogenicity of cancer chemotherapy
25. Higher risk of emesis induced by cyclophosphamide combinations containing anthracyclines
26. Prevention of chemotherapy and radiotherapy - Induced emesis: Results of the Perugia consensus conference
27. Recommendations for the use of antiemetics: Evidence-based, clinical practice guideliness
28. Ondansetron and dexamethasone versus standard combination antiemetic therapy
29. 3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting
30. Efficacy of oral ondansetron and dexamethasone in prevention of nausea and vomiting associated with moderately-high and highly emetogenic chemotherapy
31. Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?
32. Corticosteroids, dopamine antagonists and other drugs